Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Agressive or transformed MCL: prognostic factors, outcomes & mutational profile

Preetesh Jain • 2 Jul 2019
ICML 2019
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma

Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, presents the comprehensive analysis of prognostic factors, outcomes and mutation profiles in patients with mantle cell lymphoma (MCL) with an aggressive histology (blastoid/pleomorphic) or transformed MCL. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Preetesh Jain

5:06
Trials of interest in the mantle cell lymphoma space at ASH 2023
Preetesh Jain • 8 Dec 2023
0:58
Future work in mantle cell lymphoma
Preetesh Jain • 15 Jun 2023
1:32
Selecting BTK inhibitors for patients with MCL
Preetesh Jain • 15 Jun 2023
1:18
The unmet needs of patients with MCL who relapse after CAR-T
Preetesh Jain • 15 Jun 2023

Related Videos

10:31
Comparing haploSCT to other donor types in lymphoma treatment
Ali Bazarbachi • 3 May 2024
2:18
Treating patients with advanced-stage HL in the frontline and relapsed settings in 2024
Graham Collins • 29 Apr 2024
6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals